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Summary: Understanding the dynamics of naive and memory CD4+ T cells in the
immune response to HIV-1 infection can help elucidate typical disease progression
patterns observed in HIV-1 patients. Although infection markers such as CD4+ T-cell
count and viral load are monitored in patient blood, the lymphatic tissues (LT) have
been shown to be an important viral reservoir. Here, we introduce the first compre-
hensive theoretical model of disease progression based on T-cell subsets and virus
circulating between the two compartments of LT and blood. We use this model to
predict several trademarks observed in adult HIV-1 disease progression such as the
establishment of a setpoint in the asymptomatic stage. Our model predicts that both
host and viral elements play a role in determining different disease progression pat-
terns. Viral factors include viral infectivity and production rates, whereas host factors
include elements of specific immunity. We also predict the effect of highly active
antiretroviral therapy and treatment cessation on cellular and viral dynamics in both
blood and LT. Key Words: HIV-1—Homing—Naive—Memory—HAART—
Mathematical model.
To date, the mechanisms that lead to the depletion of
an HIV-1–infected individual’s blood CD4+ T cells over
a typical 10-year period of progression remain unclear.
Further, the pathways that drive a relatively constant vi-
ral titer during much of the disease to significantly in-
crease during end-stage disease are also unknown. Most
clinical indications of progression are based on blood
data, because these data are most easily obtained. Most
infection occurs in lymphatic tissues (LT), however,
where 98% of CD4+ T lymphocytes reside (1). Under-
standing the dynamics within this compartment is vital to
uncovering information regarding cellular infection and
viral production (2). Recent evidence indicates that lym-
phocyte circulation between blood and LT, which occurs
as a normal process of immune surveillance in unin-
fected individuals, is also important when studying the
effects of HIV-1 on blood lymphocytes (3–5).
Naive and memory CD4+ T-lymphocyte subsets have
differing roles during an immune response, which are
hypothesized to be important in HIV-1 disease progres-
sion and treatment. Our goal is to elucidate their roles
and describe the pathogenesis of HIV-1 infection based
on host cellular and viral factors in the blood and LT. We
use mathematical modeling as our experimental method.
This allows synthesis of the complex dynamics occurring
during the host-pathogen interaction with HIV-1 and en-
ables us to predict the mechanisms behind different out-
comes observed in patients.
In previous work, we developed a model of lympho-
cyte circulation between blood and LT in which HIV-1
binding to lymphocytes causes accelerated homing to the
lymph nodes and increased susceptibility to homing-
induced apoptosis (3). This model, which tracked pro-
ductively, latently, and abortively infected cells, sup-
ported the hypothesis that homing-induced apoptosis of
Address correspondence and reprint requests to Denise Kirschner,
Department of Microbiology and Immunology, 6730 Medical Science
Building II, The University of Michigan Medical School, Ann Arbor,
MI 48109-0620 U.S.A; e-mail: kirschne@umich.edu
Manuscript received July 24, 2001; accepted January 23, 2002.
JAIDS Journal of Acquired Immune Deficiency Syndromes
30:41–58 © 2002 Lippincott Williams & Wilkins, Inc., Philadelphia
41
nonproductively infected cells is a key mechanism for
CD4+ T-cell depletion (3). Comparison with data vali-
dated the model as a potential hypothesis for disease
progression in both compartments. We did not monitor
viral load directly, however. In this article, we introduce
naive and memory subclasses of CD4+ T cells together
with virus in both the blood and LT to determine more
mechanistically the dynamics of HIV-1 disease progres-
sion. By validating our model with experimental data, we
can use it to predict effects of highly active antiretroviral
therapy (HAART) and to interpret clinical results ob-
served with therapy and during treatment interruption.
DYNAMICS OF A HEALTHY IMMUNE SYSTEM
Cell Phenotypes
To understand the dynamics of cells during HIV-1
infection, we first describe them in a healthy uninfected
host. Newly generated naive CD4+ T lymphocytes are
input into the blood from the thymus. When naive cells
are stimulated, those that survive their role as effector
cells develop into memory cells. Combined expression of
several phenotypic markers is necessary to identify a
“pure” naive or memory population (1,6). Among sev-
eral indicators, the CD45 protein is the most common
marker for labeling a nonactivated cell as naive
(CD45RA+) or memory (CD45RO+). For consistency be-
tween studies, we consider CD4+ T cells with the
CD45RA+ and CD4+ markers and with no prior activa-
tion or exposure to antigen to be naive, whereas memory
CD4+ T cells are those with the CD45RO+ and CD4+
markers that have previously undergone activation. We
also accept that intermediates may exist based on differ-
ential expression of other proteins (7,8). Thus, when re-
ferring to data from the literature on naive and memory
cells, this is the default status unless otherwise stated.
Lymphocyte Circulation
The lymph node (LN) is the area to which T cells, B
cells, and antigen-presenting cells migrate to initiate and
participate in the adaptive immune response to foreign
pathogens (9). The adhesion molecule L-selectin
(CD62L) expressed on naive CD4+ T cells is essential for
entry of cells into the LN. The process of lymphocytes
circulating to the LNs in this fashion is referred to as
homing (7). Of the more than 1011 immune system cells
that are in constant circulation between the blood and
LT, only a small proportion of memory cells (10%)
travel to the LNs on a regular basis. The other 90%
circulate to the spleen (50%), lung, liver, bone marrow,
and other parts of the lymphoreticular system (1,10). The
purpose of this trafficking is to maintain immune sur-
veillance in all parts of the body so as to mobilize cells
to sites of secondary antigen challenge (7). It is these
mechanisms of homing that are altered during HIV-1
infection (see below).
Blood data can only provide a snapshot of immune
and viral interaction taking place in LT. By developing a
model of lymphocyte circulation between blood and LT,
we can compare experimental data (from blood) while
studying the dynamics occurring in LT. To this end, we
first develop a virtual model of adult human lymphocyte
circulation by incorporating the known circulation char-
acteristics of naive and memory cells between the blood
and LT. Our model system is depicted in Figure 1.
We develop a mathematical system to describe the
interactions in Figure 1 and estimate associated param-
FIG. 1. Healthy model. A two-
compartment model of the dynam-
ics of CD4+ naive (N) and memory
(M) cells undergoing normal pro-
cesses of lymphocyte circulation
within blood (B) and lymphatic tis-
sues (L), where e = circulation be-
tween blood and lymph tissues,
l = differentiation, S = prolifera-
tion, and µ = death. The a and b
parameters are scaling terms for
compartmental exchange.
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eters from the literature (Table 1 in Appendix). We then
simulate the model by solving the differential equation
system using appropriate numeric methods. The results
of the computational experiments are shown in Figure 2
for a representative 10-year period.
Our simulation is comparable to experimental data on
age-related decline of CD4+ naive T cells (11–13). The
proliferation of memory CD4+ T cells allows the total
CD4+ T-cell count to remain at a relative steady state
over long periods, despite the continual decline in the
number of new naive cells supplied by the thymus as a
result of involution. The total number of CD4+ T cells in
blood remains at approximately 1000 cells/mm3 with
some evidence for a gradual depletion over time (14,15),
also shown in Figure 2. This supports the theory of Haase
(16) and others who assert that homeostatic mechanisms
maintain a quasi–steady-state population in which there
is a balance of the growth of one compartment with death
in the other. Our model system thus reflects the homeo-
stasis that is observed in total CD4+ T-cell counts in
blood and LT in an average healthy adult (17). We ex-
plored variations in parameters that do not have a direct
estimate from the literature (see estimates in Table 1 in
Appendix). Results indicate that if either the direct dif-
ferentiation from naive to memory cells or the prolifera-
tion of memory cells is increased (Equation 6 in Appen-
dix), there is an overall higher population of memory
cells, but homeostasis is still maintained. If the param-
eters for memory cell proliferation are decreased by or-
ders of magnitude, homeostasis is not achieved. There-
fore, our model predicts that the processes of memory
cell production are crucial to maintaining T-cell levels in
steady state.
HIV-1 INFECTION IN THE HUMAN HOST
Disease Progression
Adult infection with HIV-1 results in three relatively
common clinical periods of acute, asymptomatic, and
end-stage disease, despite the patient-specific interaction
of the pathogen with the human immune system. A viral
setpoint is established in the acute stage and is thought to
determine the speed of progression to AIDS (18,19).
End-stage disease results in three common disease sce-
narios. Long-term nonprogressors (LTNPs) are a small
percentage (5%–10%) of the infected population who
evade the typical progression to AIDS without the help
of antiretroviral therapy for as long as 20 years (18,20,
21). In contrast, individuals whose CD4+ T-cell levels
decrease below 200 cells/mL after the 8- to 10-year
asymptomatic period while virus levels in end-stage dis-
ease increase exponentially are characterized as typical
progressors (22). Finally, some individuals develop
AIDS within 3 to 5 years after initial infection and are
known as rapid progressors. In this case, an unusually
early decline in CD4+ T-cell count may be caused by
infection with a particularly cytopathic strain or may
occur in individuals who are more susceptible to AIDS
based on factors such asimmune status at the time of
infection, age, and genetic profile. Our model predicts that
a disruption in normal homeostasis of naive and memory
cells is a crucial factor indetermining an individual’s dis-
ease progression.
HIV-1 Virus Effect on Lymphocyte Circulation and
Cellular Infection
Although conflicting hypotheses exist as to which
CD4+ T-cell subset is preferentially infected by HIV-1,
several studies support selective naive cell depletion
early in disease progression (23,24). One reason for this
may include enhanced homing-induced apoptosis of
naive cells (5,25). There is also evidence for greater deple-
tion of thymus-derived naive (CD45RA+ CD62L+) CD4+
T cells early in infection beyond involution (26–29).
A major change induced by HIV-1 binding is an al-
teration in lymphocyte circulation. HIV-1 can signal
CD45RO+ CD4+ T cells to undergo homing to lymph
nodes, a great deviation from their normal travel
FIG. 2. Healthy model results.
Temporal dynamics of naive (long
dashes), memory (short dashes),
and total (solid line) lymphocytes
during a representative 10-year pe-
riod in a healthy uninfected host.
(A) Populations in the blood (linear
scale). (B) Populations in the lym-
phatic tissues (log scale). The pa-
rameters and initial values used in
the simulations are given in Table 1
in the Appendix.
DYNAMICS OF NAIVE AND MEMORY CD4+ LYMPHOCYTES 43
JAIDS Journal of Acquired Immune Deficiency Syndromes, Vol. 30, No. 1, May 1, 2002
throughout the lymphoreticular system (25). Steady-state
levels of virus in the LT during the asymptomatic period
of infection disguise effects to lymphocyte homing and
circulation mechanisms. Throughout the course of the
disease, naive cells continue to home but at an acceler-
ated rate, whereas memory cells are recruited from their
peripheral circulation to participate in LT homing (25).
Memory T cells that circulate through the peripheral tis-
sues are spared; however, memory and naive cells cir-
culating through the LT are constant targets for viral
infection or virus-induced signaling as a result of contact
with virions or virus-producing cells (30). Given this
HIV-1–induced memory cell circulation pattern, both
memory (activated) and naive cells that come in contact
with HIV-1 are equally susceptible to apoptosis after sig-
naling through homing receptors (L-selectin or CD62L+)
occurs (25). Signaling of CD62L+ and other homing recep-
tors can induce apoptosis of HIV-1–signaled T lympho-
cytes in as much as 30% to 50% of abortively infected
(HIV-1–signaled) resting or activated cells (5,25,31).
Activation-induced cell death has also been implicated
as a major cause of CD4+ T-cell depletion. Several
sources link activation-induced cell death with homing-
induced apoptosis as described previously by showing
that activation is a direct cause of apoptosis of the host
cell or that activation is associated with apoptosis in
virus-negative cells (32,33). When infected cells or free
virions bind with neighboring uninfected cells, the unin-
fected cells become signaled, although they do not pro-
duce viral RNA (the “bystander effect”) (34,35).
We clarify for our purposes the different cell pheno-
types in our model. Productively infected cells [approxi-
mately 1 in 100,000 T cells (36)] are activated cells; thus,
viral DNA can enter the nucleus. These cells are able to
produce viral progeny, and survive no more than 2 days
(37). Provirus can survive for months or years, resulting
in a latently infected cell. If HIV-1 DNA is unable to
integrate into the nucleus and remains in the cytoplasm
of resting (naive or memory) host cells, it is unstable and
decays after a few days (25,31,36,38). These cells are
referred to as abortively infected cells. Abortive infection
can induce upregulation of L-selectin, causing most of
these cells to home. They return to the naive class after
viral DNA degrades and may participate in further hom-
ing or infection activities (25,31,36). Because 95% to
99% of T cells are resting at any given time, most in-
fections are abortive (39,40).
The model developed here elucidates possible mecha-
nisms describing differences in disease progression
based on the differential interaction of the HIV-1 virus
with the naive and memory subclasses of CD4+ T cells
together with effects to lymphocyte circulation. Our goal
is to build on our healthy model by including HIV-1
infection. We maintain varying circulation characteris-
tics of memory and naive cells as in the baseline model
and include their individual susceptibilities to infection.
Infection directly produces abortive and productively in-
fected classes of cells that are assumed to be present
predominantly in the LT compartments owing to the as-
sumption that infected cells in the blood (containing only
2% of all T cells) constitute a relatively small contribu-
tion to overall infection and that most HIV-1 replication
occurs in the LT (39–42). Latently infected cells are
derived only from productively infected cells that have
deactivated (31,43). A cell that has become abortively
infected is increased in its homing capability by upregu-
lation of L-selectin. Therefore, it is believed that most of
these cells either undergo apoptosis or revert to the naive
class if they have not been signaled through their antigen
receptors. Any cell that becomes productively infected
(whether memory or naive) must have been activated and
thus is counted as a memory cell until its death. Memory
cells and productively infected cells have a higher death
rate than naive cells (as a result of activation-induced cell
death) (32). Figure 3 depicts the dynamics of naive,
memory, and infected cells as well as virus within the
two compartments of blood and LT.
We develop a mathematical system to describe the
terms in Figure 3 and estimate associated parameters
from the literature (summarized in Appendix; see Table
2 in Appendix). We again simulate the model by solving
the differential equation system using appropriate nu-
meric methods. We discuss below the results of the com-
putational experiments in two scenarios: long-term non-
progressive infection and typical progression.
Long-Term Nonprogressors
Our purpose in developing a virtual human LTNP
model is to predict mechanisms responsible for the dy-
namics of lymphocyte circulation patterns of naive and
memory cells in an HIV-1–infected patient during the
primary, asymptomatic, and end stages of infection.
Similar to others (44), we also consider the dynamics of
memory and naive CD4+ T cells to play significant roles
in the comprehensive picture of infection. We examine
the behavior of these two cell populations in the blood
and LT over the course of disease, monitor viral load,
and compare model simulations with clinical data. Once
this is achieved, we can use the model to ask questions
about underlying mechanisms of LTNP progression. Fig-
ure 4 portrays our model simulation ofLTNP progres-
sion. Panels A, B, and C encompass cellular and viral
dynamics in the acute stage. Our simulations cor-
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relate with findings that there is a dramatic drop in CD4+
T-cell counts 3 to 6 weeks after infection (48). PanelD
depicts long-term dynamics in the blood from our model
compared with representative data over the simulated 10-
year disease course. Results were compared with those of
six patients in a study of LTNP who showed a similar
steady level of CD4+ T cells over the course of 10 years
(45). Table 3 presents a comparison of the model simula-
tions in LT with proportional data for each class of infected
cells, uninfected cells, and free virus (measured as HIV-1
RNA). By validating the results of our model against
clinical data, we then use this model to test further theo-
ries of the lymphocyte-viral interaction.
Key Parameter Dynamics
Because reaction rates likely vary among individuals
and studies, parameter values used in the model are not
exact. It is important to explore effects to the model
through uncertainty and sensitivity analyses based on
parameter variation (49). Such experiments can elucidate
model elements that may most significantly contribute to
the rapidity at which an individual progresses to AIDS as
well as to the overall pattern of lymphocyte depletion
and virus growth.
Our model predicts that several key parameters must
lie within a specific range to exhibit the standard behav-
ior of a typical HIV-1 LTNP. We explore five key pa-
rameters that are capable of dramatically changing the
typical course of disease. The primary effects of their
variation resulted in changes in onset of acute-stage dis-
ease and rapidity of progression to AIDS. These five
parameters encompass both host factors and viral factors,
indicating that all play significant roles in disease pro-
gression. Here, virulence factors of the virus include its
FIG. 3. HIV-1 model. A two-compartment model of the dynamics of CD4+ memory (M) and naive (N) cells during HIV-1 (V) infection
within blood (B) and lymphatic tissues (LT) (L), where A, L, and P = abortively, latently, productively infected cells, respectively; e =
circulation between blood and LT; l = differentiation; S = source/proliferation; r = clonal expansion; µ = death; g = immune clearance;
p, q = proportion of infected cells that become productively and abortively infected, respectively; s = activation/deactivation; k = infection,
and m = reversion to uninfected status.
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ability to infect cells as well as to produce progeny,
where an increase in either mechanism indicates an en-
hanced ability for sustained immune evasion. Host fac-
tors that play a role in HIV-1 infection likely involve
production of antigen-specific CD4+ and CD8+ T cells
against virus and virally infected cells as well as in-
creased proliferation of uninfected cells. We elaborate
these results as follows.
Viral Factors
Infection rate of naive cells by virus (kN). A low
ability to infect naive cells results in a higher CD4+
T-cell steady state and a lower viral set point. Extremely
low values of this parameter can result in clearance of
virus and no effect to homeostasis of uninfected cells. A
TABLE 3. Long-term nonprogressor model simulation values compared with experimental
data in lymphatic tissues






Latently infected cells 1.4 × 107 cells 1.0 × 105–1.2 × 107 cells 39, 67
Productively infected cells 7.0 × 107 cells 1.4 × 106–5.0 × 108 cells 16, 25, 36
Abortively infected cells 6.0 × 109 cells 109 cells 40
Viral production 2.0 × 1010 virions/cell 1010 virions/cell 99
Viral load 5.0 × 109 virions 108–1011 virions 40
FIG. 4. Long-term nonprogressor (LTNP) model results. (A–C) Acute and asymptomatic stages for cell classes in blood, cells in
lymphatic tissues (LT), and virus in both LT and blood, respectively. (D) Comparison of our model solution for longer than 8 years of
infection with data from Pantaleo et al. (45), Greenough et al. (46), and Fauci et al. (47) for CD4+ counts (l, +, ×, m, ❋) and from Pantaleo
et al. (45) for viral load (d) in the typical LTNP. The parameters and initial values are given in Table 2 in the Appendix (see Table 3 for
further comparison with data).
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large increase leads to a much higher viral setpoint with
immediate depletion of naive cells.
Infection rate of memory cells by virus (kM). A low
ability to infect memory cells results in a lower viral
setpoint and a higher CD4+ T-cell steady state. Ex-
tremely low values of kM produce a pronounced viral
decline and absence of a viral setpoint rather than viral
clearance, however. Large values of kM also lead to
higher setpoints and low levels of CD4+ memory T cells
but not depletion.
Average number of virions produced by produc-
tively infected cells (N). Experimental data indicate that
the average number of virions produced from a produc-
tively infected cell is between 100 and 1000 virions per
day per cell (25,50,51). Our model shows that values on
extreme ends of this range maintained throughout infec-
tion can dramatically alter disease course; low values result
in viral clearance, whereas high values result in an elevated
setpoint and a low total CD4+ T-cell steady state.
Host Factors
Clearance rate of productively infected cells from
LT ( gP). A previous model examined the effects of an
immune response to high viral levels produced during
acute infection, affecting the rate of viral decrease to
asymptomatic levels (52). Similarly, we consider the ef-
fects of a variable immune response in both blood and
LT. Varying the strength of the immune response over
six orders of magnitude reveals that the immune re-
sponse against productively infected cells is of key im-
portance. If the immune response is extremely efficient
from the first day of infection (gP on the order of
10−11per day per cell), the individual may clear virus.
Thus, our results imply that the strength of the immune
response to infection plays a significant role in an indi-
vidual’s eventual disease progression.
Clearance rate of free virus from blood (gV). An-
other example of the fine balance between host and viral
factors can be shown by variation of immune clearance
in the blood (gV). By varying this parameter over several
orders of magnitude, our model captures varied ability of
the immune response to combat infection. This experiment
produces different viral set point levels (Fig. 5) (19).
Note that variation in any of the 5 parameters dis-
cussed can produce the different viral setpoints.
Typical Progressors
Our LTNP virtual human model depicts steady-state
viral levels (after the acute stage) throughout the simu-
lated 10-year course of infection. If HIV-1 maintained
constant virulence and the host immune response per-
sisted (as in primary infection), the individual would ex-
hibit the behavior of the LTNP model indefinitely. As we
know through several decades of HIV-1 history, how-
FIG. 5. Effect of varying the
strength of the immune response
(gV) in the blood on the viral set
point. The increasing strength of
the immune response is indicated
by increasing line thickness (from
top to bottom), with exact values
for the parameter gV varying from
0.001 to 100.0 as shown in the
legend. Other parameters and ini-
tial values are identical to those
given in Table 2 in the Appendix
for the long-term nonprogressor
model.
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ever, this is generally not the case. Clinical data indicate
that for most individuals not receiving therapy, CD4+
T-cell levels in blood are constantly decreasing, with a
dramatic increase in virus in the final stages of disease.
To realize the viral increase observed in HIV-1 typical
progressor patients during end-stage disease, there must
likely be elements of the host-pathogen dynamic that
change over the long-term course of infection. It is be-
lieved that HIV-1 uses one or more mechanisms to
evolve and vary antigenically during infection. We con-
sider these strategies as viral factors. Alternatively, the
host may eventually lose mechanisms (host factors) that
effectively contain viral growth. Likely candidates for
host-disease elements that may evolve over time to pro-
duce AIDS in late disease are those that resulted in sig-
nificant variation in simulations when tested over a large
range in the baseline model (see previous section).
HOST AND VIRAL INFLUENCES
Virus Factors
HIV-1 is thought to become more virulent through
various mechanisms during the course of disease. After
sexual transmission, HIV-1 primarily uses the CCR5 co-
receptor expressed on CD4+ T cells (53). In many cases,
the virus may evolve to use both CCR5 and CXCR4 or
CXCR4 exclusively (16,23,53–55). Because CXCR4 is
thought to be present on most T cells (24), we represent
the increasing coreceptor repertoire by allowing the in-
fection rates (kN andkM) to increase linearly throughout
disease progression in both cell subsets (variations in this
linear increase were also tested). There is also the like-
lihood of greater replication ability over the course of
disease. This evolution could result from an increase in
the number of virions (N) produced by productively in-
fected cells during the course of infection (56,57). We
model the viral production number as also increasing
linearly from our initial value of 500 virions per day per
cell to 1000 virions per day per cell.
It is likely that in the rare rapid progressor scenario,
patients begin with rates of infection or viral production
so high that AIDS appears within 3 to 5 years. Increasing
the initial infection rates or the viral production rate or
accelerating their respective time-dependent increases
(as in the typical progressor model) by much greater
amounts than described previously results in behavior
typical of rapid progressors (data not shown).
Other virus factors that may maintain an infected in-
dividual in the asymptomatic stage could be specific to
viral strain. For example, deletions or mutations in the
nefgene of the HIV-1 viral envelope have been shown to
correlate with slower progression to AIDS (58).
Host Factors
In addition to an alteration in the numbers of CD4+ T
cells, CD8+ T cells are also affected by HIV-1 infection.
The loss of CD4+ cells is compensated for by a gain in
the number of CD8+ cells (total T-cell homeostasis) (17).
Although naive and memory CD4+ T-cell subsets de-
cline, CD8+ naive cell numbers increase slightly and
CD8+ memory cell numbers increase dramatically to
compensate and maintain T-cell homeostasis (17). The
normal ratio for CD4 to CD8 is approximately 2:1, and
reverses early in HIV+ patients to approximately 1:2 in
the blood and later in the LT (17,59,60). Our model
presently includes only CD4+ lymphocytes, although re-
cent evidence suggests that CD8+ T cells may also be
directly infected by HIV-1 (61,62). We indirectly ac-
count for their role in eliminating virally infected cells in
the immune clearance terms (Equations 11–13 and 15 in
Appendix). Activated CD8+ T-cells, or cytotoxic T-
lymphocytes (CTLs), are thought to mainly target in-
fected cells; however, because we do not include the
small proportion of infected cells in the blood, we indi-
rectly model blood CTL activity. This captures greater
clearance of infected cells from the body when the num-
ber of uninfected immune system cells is high and a
decreased ability to clear virus when CD4+ T-cell levels
fall (63). The function of this subset of cells is being
directly modeled in ongoing work.
Memory CD4+ T-cell proliferation is impaired in the
presence of HIV-1 (63). By late-stage disease, CD4+
T-cells encompass less than 10% of the total T-cell sub-
sets, with CD8+ T cells, particularly memory CD8+ T
cells, comprising the remainder (63). This is in contrast
to an uninfected individual, whose CD4+ counts remain
at approximately 66% of the total T-cell pool (63). Thus,
in the progressor scenario, we model a gradual decline in
the ability of CD4+ memory T cells to proliferate or
clonally expand by considering a time-dependent source
of memory cells.
A simulation of virtual human infection is given using
the previously discussed time-dependent parameters
(Fig. 6). Combinations of these factors result in a model
outcome similar to that observed in the classic HIV-1
patient who progresses to AIDS (the stage at which the
infected individual has less than 200 CD4+ cells/mm3 of
blood) (65) in approximately 8 to 10 years.
The LTNP and typical progressor models are distinct
in several dynamic aspects; however, viral load and
CD4+ T-cell levels are the most obvious (see Fig. 4 and
6). Recall our indirect modeling of immune activity
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through the immune clearance terms. A high level of
immune activity is observed in LTNP patients, whereas
declining immune activity is associated with typical pro-
gression (66). The distinctions in immunity between a
healthy individual, an LTNP, and a typical progressor are
shown in Figure 7. The ability of CD4+ memory T cells
to maintain homeostasis as well as to clear productively
infected cells decreases significantly in the progressor
compared with the sustained immune activity observed
in the LTNP.
HAART THERAPY
We now use our model, which is representative of
several hallmarks of HIV-1 disease progression, to de-
scribe the influence of treatment on an infected indi-
vidual. HAART acts by either reducing viral production
or blocking de novo infection or spread and typically
results in an increase in CD4+ T-cell counts during the
administration period. It is believed that therapy-induced
suppression of viral replication reduces the number of
cells that home to lymph nodes and undergo homing-
induced apoptosis, thus resulting in the reappearance of
blood lymphocytes (25). Additionally, some data indi-
cate that treatment can augment thymic output (27,28).
The output of new naive cells from the thymus has been
hypothesized not only to recover but even to increase,
countering the accelerated depletion during HIV-1
infection (27).
FIG. 6. Typical progressor model results. Model simulations of the typical progressor for both blood and lymphatic tissue (LT) com-
partments. Simulation shows average time series of CD4+ T cells and virus during HIV-1 infection. Figures are for long-term disease
progression, where the AIDS stage occurs within 10 years. Equation 6 in the Appendix shows SM (memory proliferation) as constant; we
modify this equation by allowing SM to be dependent on time. This allows for a linear decrease in the proliferation capability of memory
cells, representing a gradually decreasing ability to maintain homeostasis of the total CD4+ T-cell count. Total CD4+ T-cell population as
well as subsets of memory and naive cells (A), the two subsets in LT as well as the three classes of infected cells (B), virus (C), and
comparison with experimental data (d) from the study by Sabin et al. (64) for blood virus and from the study by Greenough et al. (46)
for blood CD4+ T cells (j) (D). The time-dependent parameters are kN, kM, N, SM, and SN as described in the Appendix. The other
parameters are the same as in Tables 1 and 2 in the Appendix for the long-term nonprogressor model.
DYNAMICS OF NAIVE AND MEMORY CD4+ LYMPHOCYTES 49
JAIDS Journal of Acquired Immune Deficiency Syndromes, Vol. 30, No. 1, May 1, 2002
Clinical Response to HAART Treatment
Several clinical studies have been performed describ-
ing qualitatively and quantitatively the effects of
HAART on the immune system. Most commonly, there
is a biphasic or multiphasic decline in viral load (30).
Virus in the blood decreases quickly for several weeks,
followed by an indefinitely prolonged decline (67).
Suppression of viral replication occurs such that virus
levels fall to undetectable levels (defined by 20 to
500 copies/mL of blood, depending on the assay) (39,
67,68).
There are distinct dynamics of memory and naive cells
during treatment. An earlier rapid rise in the memory cell
class occurs at the initiation of treatment, whereas naive
cells return later, with a more sustained response
(1,6,16,30,69–72). Several studies indicate a biphasic re-
population of CD4+ T cells: an initial increase in memory
cells over the first few months of treatment, followed by
a less dramatic rise lasting up to 1 year (71,73,74). One
study proposed that the early return of memory cells is an
interruption in HIV-1–induced circulation and virus pro-
duction, whereas the slower second phase represents im-
mune generation (69).
After cessation of drug therapy, the persistence of rest-
ing CD4+ T cells carrying replication-competent HIV-1
suggests that latently infected cells are likely to be a
major viral reservoir even if active virus replication is
suppressed by HAART for as long as 2 years (16,54,75).
The long period during which virus decays at a much
slower rate can be attributed to a low level of viral tran-
scription as well as the long half-life of latently infected
cells (up to 44 months) (76,77). This effect is seen as
HIV-1 rebounds promptly after cessation of drug therapy
in most patients (75,78,79).
Incorporating Treatment in the Infected Model
In an actual clinical setting, there is debate as to
whether HAART actually reduces viral infectivity and
production to zero, despite undetectable levels of plasma
virus and productively infected cells (80–82). Although
many models assume that infection is completely elimi-
nated at the onset of therapy, evidence suggests there is
residual viral replication occurring below the detection
limit (83). The biphasic decline also indicates that there
is more than one reservoir producing infectious particles
with varying lifespans even during the treatment window
(67). To include HAART in our model of HIV-1 disease
progression, we alter the system Equations 9, 10, and 12
through 14 (see Appendix) by reducing viral infectivity
and production by 90% on the day treatment begins. The
increase in thymic output during HAART is modeled by
a slight increase in thymic output (1% per year; see Ap-
pendix) (28).
Our model shows the effect of administering HAART
over a 108-week duration beginning 9 years after the
initial infection (Fig. 8). The model predicts that there is
a rapid decrease in all types of infected cells after the
onset of therapy. Another relevant model outcome is the
preferential elimination of infected classes. The produc-
FIG. 7. Model simulations for immune activity in three scenarios: uninfected, long-term nonprogressor (LTNP), and typical progression.
Depiction of the decreasing source of new naive cells from the thymus (SN(t)) (A); production of memory cells as a result of homeostatic
mechanisms, differentiation, and clonal expansion (SM(t) + l + r) (B); and immune clearance of productively infected cells in the lymphatic
tissues (gP(NL + ML)) (C). As seen in B, HIV-1–specific memory cells proliferate greatly in acute-stage disease for both LTNP and typical
progressors; however, only the LTNP is able to maintain this antigen-specific expansion. Additionally, in C, immune activity is immediately
impaired in acute-stage disease (in both LTNP and typical progressors) concomitant with the sudden decline in uninfected cell popula-
tions, but only the LTNP is able to recover the ability to clear uninfected cells. The time-dependent parameters for the progressor are kN,
kM, N, SN, and SM. All other parameters for the uninfected case and LTNP are the same as in Tables 1 and 2 in the Appendix.
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tively infected cells decline first as a result of their rela-
tively short half-life (37). Abortively infected cells are
the next to die out, whereas the latent reservoir declines
the slowest. The characteristic biphasic decline in viral
load is also observed. The sharp reduction of virus in
both blood and LT within the first 4 to 12 weeks of
treatment can be attributed to the relatively short half-
lives of productively infected cells and free virus (78).
Repopulation of the naive class is dependent on an indi-
vidual’s capacity for regeneration (72). We vary the rate
of increase in thymic output during treatment and ob-
serve a similar result (data not shown). Cells also return
to the blood compartment as a result of cessation of
HIV-1–induced homing and homing-induced apoptosis;
thus, an increase in the number of memory cells occurs
almost immediately at the onset of therapy (31). Our
simulation also predicts that the latent reservoir in resting
memory CD4+ T cells fails to be eradicated over a long
period (approximately 4 years; data not shown). The per-
sistence of latently infected cells, even in undetectable
amounts, causes the re-emergence of virus to more than
50 copies/mL (RNA) within weeks after discontinuing
HAART (75,84).
Panel D of Figure 8 shows the model simulation com-
pared with data for a 2-year study in which naive and
memory cells were at similar levels at the onset of the
triple therapy and all patients were previously naïve to
treatment.
Optimal Treatment Strategies
Administration of HAART is dependent on the indi-
vidual, and need is assessed on a case-by-case basis. The
FIG. 8. Effect of highly active antiretroviral therapy (HAART) on CD4+ T cells and virus in the blood and lymphatic tissues (LT). In the
model simulation, therapy was administered at 9 years and subsequently removed at 11 years. The recovery of memory and naive cells
in the blood as well as their total (A), infected cell classes in the LT (B), virus in the LT and blood (C), and comparison of CD4+ T-cell
recovery with representative data from the report by Notermans et al. (85) for memory (l) and naive (j) classes (D).
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ideal treatment schedule takes account of the host’s abil-
ity to respond to therapy as well as the level of viral
suppression. Scheduled treatment interruptions that al-
low the patient a temporary break from continuous treat-
ment regimens are becoming more common and successful
as suggested by mathematical modeling (86). The effec-
tiveness of such strategies is largely based on the individu-
al’s recovery after cessation of therapy, however. Individu-
als with impaired immune responses, even after 2 years of
therapy, may return within weeks to viral levels as high as
that present at the onset of HAART. Others may be able to
suppress viral replication successfully enough to experience
a delay in re-emergence of virus between treatments (87).
In all of our HAART simulations, treatment is administered
between years 9 and 11, and stopped at year 11. Panels A
and B of Figure 9 show the effects of suppressing viral
production and infection during treatment between 0% and
40%, with 90% as a comparison (from Figure 8). It can be
seen that when viral infectivity and production are not ef-
fectively suppressed during HAART, the viral load remains
above the detection limit or even rebounds within the
2-year treatment window. Upon cessation of therapy at year
11, the level to which CD4+ T-cell numbers decline and
virus rebounds is dependent upon an individual’s respon-
siveness to therapy. In Panels C and D we show the effect
of varying viral rebound to between 50% and 90% of pre-
treatment levels. Patients whose virus returns only after a
significant delay would be ideal candidates for treatment
interruptions, as temporary cessation of therapy would not
cause immediate viral rebound.
FIG. 9. Effect of varying treatment efficacy during and after a 2-year period on HAART. (A and B) Effect of the total CD4+ T cells and
virus in blood from variations in viral suppression during treatment. Percentages shown are differing levels of drug efficacy. (C and D)
Dynamics of T-cell decline and viral rebound after cessation of therapy based on viral rebound immediately after treatment cessation (to
between 50 and 90% of pretreatment levels). All other parameters are the same as for Figure 8.
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Our model simulations with HAART support the ex-
perimental findings that there exists a large variation in
the return of CD4+ T cells after the onset of therapy. Our
model predicts that both host and viral factors play a
significant role in recovery and maintenance of treatment
effects.
DISCUSSION
There is a significant amount of clinical and experi-
mental data describing HIV-1 disease progression in
adult humans. The mechanisms explaining the dynamics
of the host-viral interaction remain unclear, however. We
believe that including virus and infected cells in our
model as well as the nonlinear interaction of cells with
virus provides a more definitive picture of CD4+ T cells
and virus in the in vivo context of blood and LT.
In this work, we first develop a mathematical model to
capture the dynamics of naive and memory CD4+ T cells
as they undergo normal growth, death, and circulation
between the blood and LT in the absence of HIV-1 in-
fection. We then introduce HIV-1 in the model to study
how the known and hypothesized interactions of virus
and CD4+ T cells lead to different disease outcomes as
seen in clinical settings. Our simulations yield the char-
acteristic depletions of CD4+ T cells in the blood to-
gether with a relatively constant number in LT. In our
model, subtle mechanisms of circulation, alteration, and
enhanced apoptosis of naive and memory (activated)
CD4+ T cells can account for cell and viral measure-
ments commonly observed during the three typical
stages of HIV-1 disease. The model provides a means for
organizing these elements into a comprehensive quanti-
tative understanding of disease progression. It also elabo-
rates optimal routes of therapy accounting for differences
in disease progression and response to treatment between
patients based on individual-specific host and viral
factors.
The model yields both LTNP and typical progressor
outcomes. The differences seen between these patients,
as predicted by the model, are dependent on both viral
and host factors. Viral infectivity and production rates
strongly determine the progression rate of disease; this is
corroborated by studies of R5 and X4 viral strains, where
known differences in virulence are correlated with pro-
gression. The recognition and clearance of virus and in-
fected cells by the immune response also strongly influ-
ences disease progression. In the simulations, increasing
viral tropism and decreasing host response factors
strongly influence the rate of disease progression.
We also incorporate HAART in the model by reducing
viral infection and production rates and by increasing the
source of CD4+ T cells during the treatment phase.
Model simulations of HAART show a rapid return of
both lymphocyte cell subclasses, with memory preceding
the naive class. The simulations also show a biphasic
decline of virus in both blood and LT, indicating the
presence of more than one class of viral production with
differential dynamics. These phenomena are well docu-
mented in patients undergoing HAART. Consistent with
the findings of clinical studies, the model also predicts a
rapid rebound of virus when treatment is stopped. Ide-
ally, treatment would contain viral production and infec-
tivity such that treatment interruptions would be pos-
sible. Our model predicts that variations in both host and
viral factors play a significant role in the development of
an optimal treatment strategy.
APPENDIX
Model of Lymphocyte Circulation
Equations for naive (N) and memory (M) cells with theB and L
subscripts denoting populations in the blood and lymphatic tissues
(LT), respectively, are as follows:
NB8~t! = beNL NL~t! − eNB NB ~t! (1)
MB8~t! = beML ML~t! − eMB MB ~t! (2)
NL8~t! = SN~t! + aeNB NB ~t! − eNL NL ~t! − mNNL~t! (3)
ML8~t! = lmNNL~t! + SM~t! + aeMB MB ~t! − eML ML~t!
−mM ML~t! (4)
The first equation describes the rate of change of the uninfected
naive cells in the blood, NB (t). An influx of uninfected cells (NL(t))
circulating in from the LT at the rate eNL is multiplied byb to scale*
for exchange of units between compartments (from the LT to blood).
Uninfected lymphocytes (NB (t)) emigrate from blood at rate eNB to the
LT. Equation 2 encompasses the same interactions for the uninfected
memory cells in the blood. Exchange rates of memory cells to and from
blood and the LT are eML (scaled byb) and eMB, respectively. Equation
3 represents the change in the number of naive cells in the LT (NL(t))
per day. Naive cells (NB (t)) arrive from the blood compartment at rate
eNB with scaling factora and are lost to circulation (at rate eNL) or to
natural death (mN). Similarly, memory cells die naturally (at ratemM),
efflux from the LT at rate eML, or influx from the blood (eMB).
We also allow for a small percentage of naive cells to directly dif-
ferentiate from naive to memory during activation through division or
differentiation (l).
We include a source of naive cells in the LT (SN t)) similar to our
assumptions of most dynamics occurring in the LT system as opposed
* To convert between the representation of cells and virus in blood,
measured in cubic millimeters and milliliters, respectively, and that of
LT measured in total cell/virus numbers, we use scaling factors (a and
b) in the equations when describing exchange between the two com-
partments. Because there is 5 L of blood in the average human adult,
when describing movement of CD4+ T cells from blood to LT, we scale
the terms by 5 L, or 5 × 106 mL. Describing circulation in the opposite
direction, we scale by the inverse, or 2 × 10−7 mL of blood for CD4+
T-cells and 4 × 10−4 mL for virus.
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to the blood. It is believed that recent thymic emigrants of CD4+ T cells
are significantly lower in adults compared with children (27,28). To
account for the influence of a slowly decaying source during aging, we
include a decreasing input over our 10-year model time frame. The
number of thymocytes entering blood is high during the first year of life
and then decreases because of thymic involution at a rate of 5% per
year between the ages of 25 and 40 years and at a rate of 0.1% there-
after (16,88). Thus, we assume that the source of naive cells decreases
approximately 3% per year in an uninfected adult. Other ongoing work
in our laboratory explores age-dependent decline in the lymphocyte
population (89). This relation is represented by:
SN~t! = mN * NL~0! * 0.97
t
365 (5)
Similarly, the rate of change in memory cells in the LT is enhanced
by a source (SM(t)) as a result of proliferation and direct differentiation
from the naive state. To maintain homeostasis of total CD4+ T cells in
both LT and blood, we estimate a memory cell population that remains
inversely proportional to the number of naive cells. Instead of a mecha-
nistic term for non-antigen-specific proliferation, we model the rate of
change in source cells of memory class as a combination of prolifera-
tion and nonspecific antigen stimulation. This depends on the size of
the naive cell class, thus reflecting a carrying capacity–dependent
growth. Our model accounts for this mechanism with the following
relation, where R and K1 are constants (6.5 × 10






Parameter Estimation for the Healthy Model
To fully derive the model systems (Equations 1–4), values for the
parameters must be estimated. Often, parameter values can be obtained
from literature; however, discrepancies in estimates from different
sources result in a range of possible values. In this case, or when data
are not available, we employ uncertainty and sensitivity analyses to
study the effect of each parameter and explore the sensitivity of our
model to their variations (49).
Values for blood CD4+ T lymphocytes are typically measured in
cells/mm3 of blood and in total cell numbers for the lymphatic system.
To estimate the number of CD4+ lymphocytes in the blood, we begin
with the value of 2 × 1011 to 1 × 1012 total lymphocytes in the body
(4,16). Approximately 2% of these cells are present in the blood at any
given time (41), totaling approximately 5 × 109 blood lymphocytes.
Dividing this value by a blood volume of 5 L (for the average 70-kg
adult human) yields 1000 cells/mm3, the initial condition for total
CD4+ T cells (NB(0) + MB(0)). The ratio of naive to memory CD4
+ T
cells is approximately 45% to 55% in an individual by the age of 20
years, respectively, in both blood and LT (16,90–92).
The input of cells to the naive and memory classes described pre-
viously is balanced by their respective lifespans. Some data indicate
that the lifespan of a naive cell is approximately 7 weeks (7), although
other data indicate that CD45RA+ CD62L+ lymphocytes have a half-
life of 4 to 12 months (41,54). This yields a range of naïve cell death
between 0.002 and 0.02 per day. Memory cells have been shown to
have a half-life ranging from 1 to 2 months (41,54) up to almost 4
months, giving a death rate of 0.006 to 0.02 per day. Generally, it is
thought that memory cells die one to two times as fast as naive cells
because of their enhanced potential for activation, and thereby death
(6,93). Thus, we assume a death rate for memory cells that is 1.5 times
that of their naive counterparts.
Circulation rates were estimated based on the average time of 24
hours that a lymphocyte spends traveling through the LT (94,95). Lym-
phocytes exchange through the blood 48 times per day; thus, only 2%
of the entire lymphocyte pool is present at any time in the blood
(1,4,41).
In Table 1, we summarize the values used in the circulation model,
which serve as a baseline for development of the subsequent models.
Infected Model Equations
Nine nonlinear ordinary differential equations describe the dynamics
of the schematic outlined in Figure 3: four equations for rates of change




NB(0) Uninfected naive CD4
+ T cells (blood) 450 (16) Cells/mm3 of blood
MB(0) Uninfected memory CD4
+ T cells (blood) 550 (16) Cells/mm3 of blood
NL(0) Uninfected naive CD4
+ T cells (LT) 9 × 1010 (16) Cells
ML(0) Uninfected memory CD4




a Scaling term (blood→ LT) 5 × 106 mm3 or mL of blood
b Scaling term (LT→ blood) 2 × 10−7 mm3 or mL of blood
eNL Circulation of naive cells (LT to blood) 1.0 (94, 95) Day
eNB Circulation of naive cells (blood to LT) 40.0 (94, 95) Day
eML Circulation of memory cells (LT to blood) 0.25 (94, 95) Day
eMB Circulation of memory cells (blood to LT) 10.0 (94) Day
mN Death rate of uninfected naive cells (LT) 0.002 (41, 54) Day
mM Death rate of uninfected memory cells (LT) 0.003 (41, 54) Day
SN Source of naive cells into LT See Equation 5 (16, 88) Cells/day
SM Proliferation of memory cells (LT) See Equation 6 (63) Cells/day
l Direct differentiation from naive to memory cells 0.1 (estimated) Scalar
LT, lymphatic tissues.
S. H. BAJARIA ET AL.54
JAIDS Journal of Acquired Immune Deficiency Syndromes, Vol. 30, No. 1, May 1, 2002
of uninfected cells in the blood and LT (naive and memory cells), one
equation for the rate of change of virus in each compartment, and
equations for rates of change of the three infected classes in the LT:
NB8~t! = beNL NL~t! − eNB NB ~t! (7)
MB8~t! = beML ML~t! − eMB MB ~t! (8)
NL8~t! = SN~t! + aeNB NB ~t! − eNL NL ~t! − kNVL~t!NL~t!
− mNNL~t! + mAA~t! (9)
ML8~t! = lmNNL~t! + SM~t! +
rML~t!VL~t!
VL~t! + K2
+ aeMB MB ~t!
− eML ML ~t! − kMVL~t!ML~t! − mMML~t! (10)
L8~t! = sPP~t! − sLL~t! − gL~NL~t! + ML~t!! * L~t! − mLL~t! (11)
P8~t! = pavg * ~kNVL~t!NL~t! + kMVL~t!ML~t!! − gP~NL~t!
+ ML~t!! * P~t! − mPP~t! + sLL~t! − sPP~t! (12)
A8~t! = qavg * ~kNVL~t!NL~t! + kMVL~t!ML~t!!
− gA~NL~t! + ML~t!! * A~t! − mAA~t! (13)
VL8~t! = NmPP~t! − eVVL~t! − mVVL~t! (14)
VB8~t! = beVVB~t! − gV~NB ~t! + MB ~t!! * VB ~t! − mVVB ~t! (15)
Equations 7 and 8 remain as Equations 1 and 2 in the lymphocyte
circulation model, because inflow and outflow from the blood com-
partment are the same in the absence and presence of virus. Equations
9 and 10 are altered with the addition of two mass action terms at rates
kN and kM that model infection of naive and memory cells, respec-
tively. The naive class also includes the addition of cells from the
abortively infected class that revert to uninfected cells at conversion
rate of mA. T-cell production is also slightly altered during the course
of HIV-1 infection (96). It has been estimated that the source of new
thymus-derived CD4+ T cells can decline to anywhere between 10%
and 60% of the original value in some individuals, whereas there has
been almost no effect in others (1,28). Thus, it is unclear how much
thymic function is impaired in adult HIV-1 infection as well as to what
extent the disease may influence thymic involution (1). Other work
questions the general notion of thymic activity in adults (97). Thus, we
alter Equation 5 from the baseline lymphocyte circulation model to
account for an approximately 25% decrease in the source rate of new
naive cells during virtual infection. The growth of CD4+ memory T-
cells in the lymphocyte circulation model was adequate to maintain an
average of 1000 cells/mm3. However, as our model simulations show,
long-term nonprogressors (LTNPs) are able to maintain the immune
response to infection through enhanced growth of the CD4+ memory
class beyond normal levels as a result of HIV-1 antigen presentation.
This clonal expansion is reflected in a source of memory cells that
proliferates proportional to the amount of antigen or virus present in the
LT. Thus, we reflect this enhanced growth as a result of HIV-1 antigen
presentation in Equation 4 from our baseline model by adding a term
for HIV-1 antigen-induced memory cell proliferation, wherer andK2
are constants (0.005 and 5 × 108, respectively).
Equations 11 through 13 describe the rate of change in infected
classes in the LT: latently (L(t)), productively (P(t)), and abortively
(A(t)) infected cells. Infection of naive or memory cells directly leads
to productive or abortive infections in proportions p and q, respectively.
Each class has a natural life span or death rate. Latently infected cells
can be activated and become productively infected at rate sL, or pro-
ductively infected cells can deactivate at rate sP. The distinction be-
tween proportions of naive and memory cells that become productively
or abortively infected has not yet been determined experimentally.
Therefore, we model the contribution of infection from each class as an
average proportion (pavg and qavg) based on estimates from data
(37,40). Apoptosis of abortively infected cells is modeled as in previ-
ous work (3). This loss is described by estimating the value of mA to
account for the proportion of abortively infected cells (A(t)) that revert
back to uninfected naive cells after a short period. Thus, the number of
cells undergoing apoptosis i1 − pavg − qavg.
Virus is present in both the LT (VL(t)) and blood (VB(t)) compart-
ments. Virus in the LT grows proportional to the number of produc-
tively infected cells. Of these virus-producing cells, each produces, on
average,N virions over its life span (98). The only source of virus in
blood is derived from the LT. Entry occurs at rate eV, scaled byb.
There is a representative immune response against infected cell
classes. The immune response to infection occurs primarily through the
activity of CD8+ CTLs acting on infected cells. There is a mass action
immune response term in the LT for the three classes of infected cells
at ratesgL, gP, andgA. Because infected classes are not present in the
blood compartment in our model, we indirectly model immune activity
in the blood withgV, accounting for general clearance of virions in the
blood. The immune response term of the formgi(Mj + Nj) is repre-
sented as a function of the immune cells present at any given time
point. In accordance with certain theories that DNA in latently infected
cells remains invisible to immune surveillance, we investigate removal
of the immune response to latently infected cells. We find that this
makes no qualitative difference in disease progression.
Parameter Estimation for the Infected Model
The values used for the infection parameters presented in the LTNP
model are detailed in Table 2. Virus titer in blood is typically measured
as RNA copies/mL, whereas the lymphatic system is measured in total
viral numbers. We outline below how we estimated their values. Our
model steady states are robust to small changes in these parameter
values as our sensitivity analyses confirm (see below).
Because the model is initiated at inoculum, other than the small
amount of virus introduced in the LT, the initial conditions reflect that
the other infected classes begin at zero.
Lifespans of productively infected cells are orders of magnitude
shorter than those of uninfected cells. It is estimated that productively
infected cells live for only 1 to 2 days (37,90,99), producing an ad-
equate number of virions to infect new cells and sustain infection for
years. One or 2 days after infection, most of the abortively infected
cells have circulated back to the blood, undergoing rapid homing to the
lymph nodes, where approximately 50% undergo apoptosis (5,25). The
remainder of abortively infected cells can revert to the uninfected
memory class after a period of 5 days based on the half-life of viral
DNA (25), becoming potential candidates for future infection. Latently
infected cells harbor integrated provirus. Sources claim this viral res-
ervoir has a half-life of anywhere from 6 to 44 months (67,76,77). Of
all the model components in our system, free virus has the shortest
half-life of approximately 6 hours (19).
Infection rates of naive (kN) and memory (kM) cells account for
infection of each cell subset meeting virus within the LT. These rates
have been estimated per day per virion. We estimate an infection rate
for naive cells greater than that for memory cells based on the discus-
sion in the previous section.
The proportion of infected cells of each type is a subject of debate,
mainly because of differences in classification from one study to the
next. Productively infected cells are easiest to characterize because they
are actively producing virus. This proportion is approximately 5 to 10
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cells per million or 105 per gram of lymphoid tissue (∼1 in 100,000
cells) (16). The number of latently infected cells is similarly small,
ranging from about 0.1% to 1% of the total number of infected cells or
approximately 5 to 10 latently infected cells per million (40). Latently
infected cells do not result from direct infection but from deactivation
of productively infected cells (31,36). Abortively infected cells, resting
cells that have come in contact with virus, exist at a ratio of about 7500
per million. Approximately 30% to 50% have been observed to un-
dergo apoptosis (25).
A single productively infected cell can produce anywhere from 102
to 103 virions (25,50,51). As a starting estimate, we use a baseline
value of viral production as 500 virions per day per cell and explore the
full variation of this parameter within the text.
Because the CD4/CD8 ratio is observed to switch early in infection
from 2:1 to 1:2 (17), our model indirectly accounts for this in our
representation of the immune response. We model the CD8+ T-cell
response as proportional to the number of CD4+ T cells present at any
given point in disease progression.
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L(0) Latently infected CD4+ T cells (LT) 0 Cells
P(0) Productively infected CD4+ T cells (LT) 0 Cells
A(0) Abortively infected CD4+ T cells (LT) 0 Cells
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